MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies (NCT05735717)
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR ฮฑ/ฮฒ TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
Who can join: Review the eligibility criteria below.
Location: University of Minnesota Masonic Cancer Center โ Minneapolis, Minnesota
Age range: Not specified to 60 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University of Minnesota Masonic Cancer Center โ Minneapolis, Minnesota
๐ Contact the Study Coordinator
Phone: (612) 626-2961
Email: macmi002@umn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Malignancy
- A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors โ Boston, Massachusetts
- Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation โ New York, New York
- Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity โ Winston-Salem, North Carolina
- Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation โ Seattle, Washington
- Critical Care Outcomes of Hematologic Oncology Patients โ Calgary, Alberta
- Expressive Writing Program Among Young Adults With Blood Cancer โ Washington D.C., District of Columbia
Explore by condition: All Hematologic Malignancy clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.